دورية أكاديمية
أعرض في EDS

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

التفاصيل البيبلوغرافية
العنوان: High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
المؤلفون: Paiva, Bruno1,2, Gutiérrez, Norma C.1,2, Rosiñol, Laura3, Vídriales, María-Belén1,2, Montalbán, María-Ángeles4, Martínez-López, Joaquín4, Mateos, María-Victoria1,2, Cibeira, María-Teresa3, Cordón, Lourdes5, Oriol, Albert6, Terol, María-José7, Echeveste, María-Asunción8, de Paz, Raquel9, de Arriba, Felipe10, Palomera, Luis11, de la Rubia, Javier5, Díaz-Mediavilla, Joaquín12, Sureda, Anna13, Gorosquieta, Ana14, Alegre, Adrian15
المصدر: Blood. 1/19/2012, Vol. 119 Issue 3, p687-691. 5p.
مصطلحات موضوعية: *CYTOGENETICS, *FLOW cytometry, *STEM cell transplantation, *MULTIPLE myeloma, *DISEASE progression
مستخلص: The achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; however, patients who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis. Thus, the identification of these patients is highly relevant. Here, we investigate which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n = 140) and GEM2005 < 65y (n = 101) trials. Twenty-nine (12%) of the 241 patients showed unsustained CR and a dismal outcome (median overall survival 39 months). The presence of baseline high-risk cytogenetics by FISH (hazard ratio 17.3; P = .002) and persistent minimal residual disease by multiparameter flow cytometry at day +100 after HDT/ASCT (hazard ratio 8.0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:00064971
DOI:10.1182/blood-2011-07-370460